

FOR OFFICE USE ONLY	

HOUSE FLOOR AMENDMENTS

2017 Regular Session

Amendments proposed by Representative Talbot to Engrossed House Bill No. 436 by
Representative Talbot

1 AMENDMENT NO. 1

2 On page 1, line 2, after "To" delete "amend and reenact R.S. 44:4.1(B)(26) and to enact R.S.
3 22:1060.7 and" and insert in lieu thereof "enact"

4 AMENDMENT NO. 2

5 On page 1, delete lines 4 through 11 in their entirety and insert in lieu thereof the following:

6 "of R.S. 40:2255.1 and 2255.11, relative to prescription drug prices; to
7 provide for definitions; to require disclosure of prescription drug price
8 information; and to provide for related matters."

9 AMENDMENT NO. 3

10 On page 1, after line 12, delete the remainder of the page and on page 2, delete lines 1
11 through 20 in their entirety

12 AMENDMENT NO. 4

13 On page 2, line 21, change "Section 2." to "Section 1."

14 AMENDMENT NO. 5

15 On page 2, line 22, change "2255.21" to "2255.11"

16 AMENDMENT NO. 6

17 On page 2, after line 24, delete the remainder of the page and on page 3, delete lines 1
18 through 3 in their entirety

19 AMENDMENT NO. 7

20 On page 3, at the beginning of line 4, change "§2255.2" to "§2255.1"

21 AMENDMENT NO. 8

22 On page 3, delete lines 7 through 21 in their entirety

23 AMENDMENT NO. 9

24 On page 3, at the beginning of line 22, change "(5)" to "(1)"

25 AMENDMENT NO. 10

26 On page 3, at the beginning of line 23, change "(6)" to "(2)"

1 AMENDMENT NO. 11

2 Delete pages 4 through 6 in their entirety and on page 7, delete lines 1 through 8 in their
3 entirety

4 AMENDMENT NO. 12

5 On page 7, line 9, after "Subpart" change "C." to "B."

6 AMENDMENT NO. 13

7 On page 7, after line 9, delete the remainder of the page and delete page 8 in its entirety and
8 insert in lieu thereof the following:

9 "§2255.11. Disclosure of prescription drug price information

10 Each drug manufacturer or pharmaceutical marketer who engages in
11 any form of prescription drug marketing to a prescriber, his designee, or any
12 member of his staff in Louisiana shall provide to the Louisiana Board of
13 Pharmacy no later than January first, April first, July first, and October first
14 of each calendar year the current wholesale acquisition cost information for
15 the United States Food and Drug Administration approved drugs marketed
16 in the state by that manufacturer."